DealForma

Our Q3 2024 healthcare and life sciences overview explores significant developments across R&D, M&A, ventures, and IPOs. GSK and Flagship Pioneering partnered on respiratory and autoimmune treatments with a $150 million upfront and up to $720 million in future payments, while Dren Bio, Inc. and Novartis secured a $125 million deal for cancer therapies, with potential earnings of $2.9 billion. ImmuneOnco teamed with Instil Biofor cancer therapy commercialization, receiving $10 million upfront and up to $2.1 billion in milestones. Check out our research https://hubs.ly/Q02TTnhj0

Don't miss this exclusive webinar with DealForma and Pragma Bio, featuring guest speaker Orly Levitan. Get an inside look at Pragma Bio's latest innovations and gain valuable insights from industry experts! Register for the event!

Stifel’s weekly biopharma update, using data from DealForma, provides an update on the biopharma market for the week of October 7, 2024, discussing strong U.S. jobs data, geopolitical tensions, market volatility, a China stimulus, trends in biotech stocks, capital raising activities, and M&A developments ahead of the U.S. presidential election. Check out Stifel’s report. https://hubs.ly/Q02TGfcH0

Our H1 2024 endocrine and metabolic review highlights significant activity across R&D partnerships, M&A, venture funding, and IPOs primarily targeting diabetes, obesity, and metabolic disorders. Key R&D partnerships included TreeFrog Therapeutics April 2024 collaboration with Vertex Pharmaceuticals to develop stem cell therapies for type 1 diabetes, potentially worth $540 million in milestones. In May, Metaphore Biotechnologies partnered with Novo Nordisk on obesity treatments, with the deal valued at up to $600 million in milestones. Similarly, Omega Therapeutics secured a deal with Novo Nordisk in January for an epigenomic controller targeting obesity, potentially earning $532 million. Check out the rest of our research. https://hubs.ly/Q02T7lNj0

Our H1 2024 endocrine and metabolic review goes deeper into key R&D partnerships, M&A activity, and venture funding. In April, TreeFrog Therapeutics partnered with Vertex Pharmaceuticals to develop stem cell therapies for type 1 diabetes, securing $25 million upfront with potential milestones totaling $755 million. In May, Metaphore Biotechnologies struck a $600 million deal with Novo Nordisk to develop GLP-1 receptor agonists for obesity. Omega Therapeutics also teamed up with Novo Nordisk in January for an epigenomic controller for obesity, with up to $532 million in potential earnings. Check out the rest of our research on our blog. https://hubs.ly/Q02S3MLl0

See how Pragma Bio used DealForma’s platform to drive business growth, improve decision-making, and streamline processes. Read the full case study to learn more about their journey and results https://hubs.ly/Q02RxktS0

Our Q2 2024 neurology review provides an in-depth analysis of R&D and licensing partnerships, M&A deals, and venture activity, highlighting strong momentum in the sector. AC Immune partnered with Takeda in May to license and commercialize ACI-24.060 for Alzheimer’s, securing $100 million upfront and up to $2.1 billion in milestones. In May, AbbVie partnered with Gilgamesh Pharmaceuticals to develop neuroplastogen therapies for psychiatric disorders, with $65 million upfront and potential payments of up to $2.0 billion. Check out the rest of our research on our blog. https://hubs.ly/Q02RgPQ90

Our Q2 2024 neurology report reviews financial activity in R&D licensing partnerships, M&A, venture investments, and IPOs. AC Immune partnered with Takeda in May, licensing its Alzheimer’s immunotherapy ACI-24.060 for $100 million upfront, with potential milestones of up to $2.1 billion. AbbVie and Gilgamesh Pharmaceuticals teamed up on neuroplastogen therapies for psychiatric disorders in May, offering $65 million upfront with $2.0 billion in potential milestones. Ascidian Therapeutics and Roche collaborated in June to develop RNA exon editing for neurological diseases, with a $42 million upfront payment and up to $1.8 billion in milestones. Check out the rest of our research on our blog. https://hubs.ly/Q02Ql_Sj0

Our Q2 2024 cancer review delves into significant R&D partnerships, M&As, and ventures reflecting strong activity for the sector. Peptidream and Novartis expanded their peptide-drug conjugate collaboration in April, potentially valuing at $2.7 billion, with an upfront payment of $180 million. Similarly, Caris Life Sciences partnered with Merck on antibody-drug conjugates for cancer, with milestones potentially reaching $1.4 billion. On the M&A front, ONO PHARMACEUTICAL CO., LTD. acquired Deciphera Pharmaceuticals for $2.4 billion in June, enhancing its oncology portfolio with several promising drug candidates. Read the rest of our research on our blog. https://hubs.ly/Q02PKZ0M0

Our Q2 2024 cancer review delves into R&D and licensing partnership activity, investments, IPOs and M&A. In R&D, Peptidream expanded its peptide-drug conjugate partnership with Novartis in April, potentially earning up to $2.7 billion, while Caris Life Sciences teamed up with Merck to develop antibody-drug conjugates, with the deal valued at $1.4 billion. Kumquat Biosciences Inc. partnered with Takeda on immuno-oncology therapies, securing up to $1.2 billion in potential payments. Check out our research. https://hubs.ly/Q02N-jys0